Diese Seite wurde automatisch übersetzt und die Genauigkeit der Übersetzung wird nicht garantiert. Bitte wende dich an die englische Version für einen Quelltext.

Multidimensional Dysfunction in Patients With Post-Intensive Care Syndrome in China: A Multi-center Real-world Study

8. Mai 2026 aktualisiert von: Hongying Jiang, MD
Over the past two decades, the rapid advancement of critical care medicine has significantly reduced short-term mortality among critically ill patients. However, a growing number of intensive care unit (ICU) survivors experience persistent physical, cognitive, and psychological impairments after hospital discharge, a syndrome termed post-intensive care syndrome (PICS). Although PICS has gained increasing attention in recent years, existing studies still have multiple limitations. Given the continuously increasing number of ICU survivors in China and the marked heterogeneity in critical care delivery models across different regions and healthcare institutions, there is an urgent need for large-scale multicenter observational studies to systematically characterize the epidemiological features, multidimensional functional impairment profiles, and clinical impact of PICS in Chinese patients, thereby providing an evidence-based foundation for the development of a scientific post-ICU continuum of care.

Studienübersicht

Status

Noch keine Rekrutierung

Bedingungen

Intervention / Behandlung

Detaillierte Beschreibung

This multi-center observational study aims to characterize the epidemiological profile and multidimensional functional impairments of Post-Intensive Care Syndrome (PICS) in ICU survivors across China. The study will enroll approximately 800 participants from six participating centers (three high-dependency units from 2018-2026 and three ICUs from 2025-2026). Data on physical, cognitive, and psychological function will be collected using validated assessment tools including MRC, ICU Mobility Scale, CPAx, MMSE, S5Q, PHQ-9, GAD-7, PSQI, Barthel Index, and EQ-5D-5L. Primary outcomes include the incidence of PICS and comorbidity patterns across multiple functional domains. Secondary outcomes encompass functional status, quality of life, and risk factors for PICS.

Studientyp

Beobachtungs

Einschreibung (Geschätzt)

800

Kontakte und Standorte

Dieser Abschnitt enthält die Kontaktdaten derjenigen, die die Studie durchführen, und Informationen darüber, wo diese Studie durchgeführt wird.

Studienkontakt

Studieren Sie die Kontaktsicherung

  • Name: Hongying Jiang, MD
  • Telefonnummer: +861056981098
  • E-Mail: 6jhy@163.com

Studienorte

  • China
    • Beijing Municipality
      • Beijing, Beijing Municipality, China, 100043
        • Beijing Rehabilitation Hospital, Capital Medical University, Beijing,China

Teilnahmekriterien

Forscher suchen nach Personen, die einer bestimmten Beschreibung entsprechen, die als Auswahlkriterien bezeichnet werden. Einige Beispiele für diese Kriterien sind der allgemeine Gesundheitszustand einer Person oder frühere Behandlungen.

Zulassungskriterien

Studienberechtigtes Alter

  • Erwachsene
  • Älterer Erwachsener

Akzeptiert gesunde Freiwillige

Nein

Probenahmeverfahren

Wahrscheinlichkeitsstichprobe

Studienpopulation

This study is a multi-center, retrospective, observational cohort study that will enroll patients from six participating centers across China, including three high-dependency units (HDUs) and three ICUs. For the HDU component, patients transferred from general hospital ICUs to the participating HDUs between January 2018 and January 2026 will be screened. For the ICU component, patients scheduled for discharge directly from the participating ICUs between January 2025 and January 2026 will be screened. Data will be sourced from medical records, nursing records, rehabilitation assessment records, and follow-up documentation from routine clinical care. The anticipated total sample size is 800 participants.

Beschreibung

Inclusion Criteria:

  • Age ≥18 years
  • Admitted to ICU from participating general hospitals and transferred to participating High-Dependency Units (HDUs) or discharged directly from participating ICUs
  • First ICU admission with ICU length of stay ≥48 hours
  • Complete clinical data available (demographics, ICU-related information)
  • Signed informed consent obtained from participants or legal guardians

Exclusion Criteria:

  • Prior ICU admission
  • Terminal illness or estimated life expectancy <6 months
  • Participants or family members refuse to complete questionnaires

Studienplan

Dieser Abschnitt enthält Einzelheiten zum Studienplan, einschließlich des Studiendesigns und der Messung der Studieninhalte.

Wie ist die Studie aufgebaut?

Designdetails

Kohorten und Interventionen

Gruppe / Kohorte
Intervention / Behandlung
post-intensive care syndrome group
PICS patients who come from a general hospital ICU and are transferred to a participating HDU, or who are planned for discharge from a participating ICU.
Sonstiges: Data Collection and Assessment
  1. General clinical data collection: demographic characteristics, primary disease, duration of tracheostomy tube retention, duration of mechanical ventilation before transfer, and length of ICU stay before transfer; history of organ dysfunction; tube/catheter status; disease severity; nutritional status.
  2. Physical function assessment: diaphragmatic excursion, diaphragm thickness, thickening fraction, PEF; Medical Research Council score for muscle strength, ICU Mobility Scale; comprehensive score: Chelsea Critical Care Physical Assessment Tool score.
  3. Cognitive function assessment: Standardized Five Questions，Mini-Mental State Examination.
  4. Psychological status assessment: Patient Health Questionnaire-9 for depression, Generalized Anxiety Disorder 7-item scale , Pittsburgh Sleep Quality Index, Brief Pain Inventory-9, Hospital Anxiety and Depression Scale for family caregivers.
  5. Quality of life and functional capacity: Barthel Index, EQ-5D-5L.

Was misst die Studie?

Primäre Ergebnismessungen

Ergebnis Maßnahme
Maßnahmenbeschreibung
Zeitfenster
MRC Sum Score for Muscle Strength
Zeitfenster: Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
MRC (Medical Research Council) sum score assessing muscle strength. Total score ranges from 0 (complete quadriplegia) to 60 (normal bilateral muscle strength). Higher scores indicate better muscle strength.
Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
ICU Mobility Scale Score
Zeitfenster: Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
ICU Mobility Scale (IMS) assessing mobility level in ICU patients. Total score ranges from 0 (lying in bed, not active) to 10 (walking independently). Higher scores indicate better mobility.
Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Chelsea Critical Care Physical Assessment Tool Score
Zeitfenster: Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Chelsea Critical Care Physical Assessment Tool (CPAx) comprehensively evaluating physical function in ICU patients. Total score ranges from 0 to 50. Higher scores indicate better physical function.
Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Mini-Mental State Examination Score
Zeitfenster: Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Mini-Mental State Examination (MMSE) assessing cognitive function. Total score ranges from 0 to 30. Higher scores indicate better cognitive function. (Chinese validated version will be used.)
Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
PHQ-9 Score for Depression
Zeitfenster: Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Patient Health Questionnaire-9 (PHQ-9) assessing severity of depressive symptoms. Total score ranges from 0 to 27 (0-4: none, 5-9: mild, 10-14: moderate, 15-19: moderately severe, 20-27: severe). Higher scores indicate worse depression.
Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
GAD-7 Score for Anxiety
Zeitfenster: Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Generalized Anxiety Disorder 7-item scale (GAD-7) assessing severity of anxiety symptoms. Total score ranges from 0 to 21 (0-4: none, 5-9: mild, 10-14: moderate, 15-21: severe). Higher scores indicate worse anxiety.
Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Pittsburgh Sleep Quality Index Global Score
Zeitfenster: Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Pittsburgh Sleep Quality Index (PSQI) assessing sleep quality. Global score ranges from 0 to 21. Higher scores indicate worse sleep quality.
Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Brief Pain Inventory-9 Pain Severity Score
Zeitfenster: Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Brief Pain Inventory-9 (BPI-9) pain severity score. Total score ranges from 0 to 10. Higher scores indicate more severe pain.
Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Hospital Anxiety and Depression Scale Score for Family Caregivers
Zeitfenster: Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.
Hospital Anxiety and Depression Scale (HADS) assessing psychological status of family caregivers. Each subscale (anxiety and depression) ranges from 0 to 21. Higher scores indicate worse psychological distress.
Collect data within 24 hours after admission to the HDU or within 24 hours before discharge from the ICU.

Mitarbeiter und Ermittler

Hier finden Sie Personen und Organisationen, die an dieser Studie beteiligt sind.

Sponsor

Hongying Jiang, MD

Studienaufzeichnungsdaten

Diese Daten verfolgen den Fortschritt der Übermittlung von Studienaufzeichnungen und zusammenfassenden Ergebnissen an ClinicalTrials.gov. Studienaufzeichnungen und gemeldete Ergebnisse werden von der National Library of Medicine (NLM) überprüft, um sicherzustellen, dass sie bestimmten Qualitätskontrollstandards entsprechen, bevor sie auf der öffentlichen Website veröffentlicht werden.

Haupttermine studieren

Studienbeginn (Geschätzt)

10. Mai 2026

Primärer Abschluss (Geschätzt)

31. Dezember 2026

Studienabschluss (Geschätzt)

31. Mai 2027

Studienanmeldedaten

Zuerst eingereicht

1. Mai 2026

Zuerst eingereicht, das die QC-Kriterien erfüllt hat

8. Mai 2026

Zuerst gepostet (Tatsächlich)

14. Mai 2026

Studienaufzeichnungsaktualisierungen

Letztes Update gepostet (Tatsächlich)

14. Mai 2026

Letztes eingereichtes Update, das die QC-Kriterien erfüllt

8. Mai 2026

Zuletzt verifiziert

1. Mai 2026

Mehr Informationen

Begriffe im Zusammenhang mit dieser Studie

Schlüsselwörter

Zusätzliche relevante MeSH-Bedingungen

Andere Studien-ID-Nummern

  • 2026bkky-dzx-PICS

Arzneimittel- und Geräteinformationen, Studienunterlagen

Studiert ein von der US-amerikanischen FDA reguliertes Arzneimittelprodukt

Nein

Studiert ein von der US-amerikanischen FDA reguliertes Geräteprodukt

Nein

Diese Informationen wurden ohne Änderungen direkt von der Website clinicaltrials.gov abgerufen. Wenn Sie Ihre Studiendaten ändern, entfernen oder aktualisieren möchten, wenden Sie sich bitte an register@clinicaltrials.gov. Sobald eine Änderung auf clinicaltrials.gov implementiert wird, wird diese automatisch auch auf unserer Website aktualisiert .

Klinische Studien zur Post-Intensive-Care-Syndrom (PICS)

Klinische Studien zur Data Collection and Assessment

Suchen Sie nach ähnlichen Studien

Sponsoren und Mitarbeiter

Krankheiten

Drogeninterventionen

CROs by country

CROs in New Zealand

Bedingungen

Seltene Krankheiten

Drogeninterventionen

Nahrungsergänzungsmittel

Sponsor / Mitarbeiter

Standorte

Abonnieren